EP Patent

EP2186808B1 — Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Assigned to Novartis AG · Expires 2017-04-19 · 9y expired

What this patent protects

Patent listed against nilotinib-hydrochloride.

Drugs covered by this patent

Patent Metadata

Patent number
EP2186808B1
Jurisdiction
EP
Classification
—
Expires
2017-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.